Trial Profile
A randomised, double-blind, single-dose study to compare pharmacokinetic characteristics and safety of FKB238 with those of Avastin in healthy male subjects (HMR code 14-009)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Apr 2022
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary)
- Indications Non-small cell lung cancer; Solid tumours
- Focus First in man; Pharmacokinetics
- Sponsors Fujifilm Kyowa Kirin Biologics
- 01 Apr 2022 Results published in the International Journal of Clinical Pharmacology and Therapeutics
- 02 Jun 2017 Status changed from recruiting to completed, according to results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 02 Jun 2017 Primary endpoint (Pharmacokinetic parameter: AUC0-t) has been met, according to results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.